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A newmyositis-specific autoantibody directed againstmelanomadifferentiation-associated gene 5 (anti-MDA5) has been described
in patients with dermatomyositis (DM). We report the clinical characteristics of patients with anti-MDA5 in a large Mediterranean
cohort of DMpatients from a single center, and analyze the feasibility of detecting this autoantibody in patient sera using new assays
with commercially available recombinant MDA5. The study included 117 white adult patients with DM, 15 (13%) of them classified
as clinically amyopathic dermatomyositis (CADM). Clinical manifestations were analyzed, with special focus on interstitial lung
disease and its severity. Determination of anti-MDA5 antibodies was performed by a new ELISA and immunoblot technique. In
sera, from 14 (12%) DM patients (8 CADM), MDA5 was recognized by ELISA, and confirmed by immunoblot. Eight of the 14
anti-MDA5-positive patients (57.14%) presented rapidly-progressive interstitial lung disease (RP-ILD) versus 3 of 103 anti-MDA5-
negative patients (2.91%) (𝑃 < 0.05; OR: 44.4, 95% CI 9.3–212).The cumulative survival rate was significantly lower in anti-MDA5-
positive patients than in the remainder of the series (𝑃 < 0.05). Patients with anti-MDA5-associated ILD presented significantly
lower 70-month cumulative survival than antisynthetase-associated ILD patients. Among the cutaneous manifestations, only
panniculitis was significantly associated with the presence of anti-MDA5 antibodies (𝑃 < 0.05; OR: 3.85, 95% CI 1.11–13.27).
These findings support the reliability of using commercially available recombinant MDA5 for detecting anti-MDA5 antibodies
and confirm the association of these antibodies with RP-ILD in a large series of Mediterranean patients with DM.
1. Introduction
In 2005, Sato et al. [1] identified a novel autoantibody recog-
nizing a 140-kDa protein in patients with dermatomyositis
(DM), particularly in those with clinically amyopathic der-
matomyositis (CADM).The 140-kDa autoantigen, which was
identified as melanoma differentiation-associated protein 5
(MDA5), is detected in 19% to 35% of the patients with
DM. In the Asian population, this autoantibody seems to be
associated with rapidly progressive interstitial lung disease
and with severe cutaneous vasculopathy (skin ulceration,
tender palmar papules, or both) [1–6]. Recently, the presence
of anti-MDA5 antibody-associated dermatopulmonary syn-
drome was described in the white population [7–9].
MDA5, also known as interferon-induced helicase-1
(IFIH1), is a member of the retinoic acid-inducible gene I-
like helicase (RIG-I or RLH) family of proteins, [10] which
function by recognizing single-stranded RNA viruses and are
involved in the innate immune response, including type I IFN
production [11].
The main drawback to routine use of this antibody
for clinical purposes is that its determination is limited to
techniques that are only available in research laboratories,
such as immunoprecipitation of radioactive-labeled protein
[8] or enzyme-linked immunoassay (ELISA) using in-house
fabricated recombinant proteins [12, 13].
Our objective was to evaluate the prevalence and clinical
manifestations of anti-MDA5-positive patients in a large
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cohort of DM patients from a single center in Barcelona, and
to determine the feasibility of detecting this autoantibody
with the use of more widely available techniques (ELISA and
immunoblotting) with commercially available recombinant
MDA5 as the antigen.
2. Patients and Methods
2.1. Patient Population. This study was performed in 117 adult
patients (92 women) with DM (15 with clinically amyopathic
DM). In addition, 45 patients with polymyositis (PM), 30
with systemic sclerosis (SSc), and 25 with systemic lupus
erythematosus (SLE) were included as controls. Twenty-
five healthy controls were also included to determine the
cut-off value for establishing the positive status by ELISA.
Healthy and disease controls were age and sex matched to
the DM patients. The median age of DM patients was 52
years (range 22–81).Thepatients studied belong to a historical
cohort diagnosed with idiopathic inflammatory myopathy
at Vall d’Hebron General Hospital in Barcelona (Spain),
between 1983 and 2012. Our center is a single teaching
hospital with approximately 700 acute care beds, attending
a population of nearly 450,000 inhabitants. All myositis
patients in this population are referred to our hospital for
diagnosis and therapy, regardless of the severity of the disease.
Serum samples from these patients are routinely collected at
diagnosis and during follow-up in our outpatient clinic, and
stored at −80∘C. Patients and controls included in the study
gave informed consent for the use of their serum for research
purposes.The study was approved by the institutional review
board of our hospital.
The diagnosis of DM and PM was based on the criteria
of Bohan and Peter [14, 15]. Only patients with definite
or probable disease were included. The Sontheimer criteria
were used to diagnose amyopathic DM [16]. Interstitial lung
disease (ILD) was diagnosed according to the consensus
classification of idiopathic interstitial pneumonias. The diag-
nosis of ILD was established by high-resolution CT findings,
and rapidly progressive-interstitial lung disease (RP-ILD)was
defined as a worsening of radiologic interstitial changes with
progressive dyspnea and hypoxemia within 1 month after the
onset of respiratory symptoms. [17] Cancer-associatedmyosi-
tis (CAM) was defined as cancer occurring within 3 years
of the myositis diagnosis. Patients received treatment with
corticosteroids and immunosuppressive drugs (methotrex-
ate, azathioprine, calcineurin inhibitors [cyclosporine A or
tacrolimus], or cyclophosphamide pulses) were added when
needed; intravenous immunoglobulin was used as an adju-
vant therapy, and biological therapy (rituximab) was also
instituted when possible in refractory cases. A drug trial
was defined as a single course from the beginning of the
administration of a given drug to the time at which the drug
was discontinued, or in the case of prednisone, as the time at
which the dose was reduced to one quarter of the initial dose.
Clinical data were obtained retrospectively by review of the
patients’ medical records.
2.2. Laboratory Tests and Serological Assay. Serum samples
from each patient were screened by indirect immunofluores-
cence for antinuclear antibodies (ANA) using HEp-2 cells,
and by a commercial ELISA used in our routine laboratory
setting for antibodies against extractable nuclear antigens
(Ro, La, RNP, Sm) and anti-histidyl-tRNA synthetase (anti-
Jo-1). Anti-TIF1𝛾 antibodies were detected by an in-house
ELISA and confirmed by immunoblot [18]. In addition, all
samples were tested by protein and RNA immunoprecipita-
tion [19], which enabled detection of other synthetases and
myositis-specific and myositis-associated antibodies (anti-
Mi-2, anti-SRP, anti-Ro52, anti-Ro60, anti-La, anti-PM/Scl,
anti-p155, and anti-U1RNP) that may have been overlooked
by ELISA, and confirmed the ELISA results.
2.3. Anti-MDA5 ELISA. Briefly, 96-well ELISA plates
(NUNC, Kamstrup, Denmark) were coated with 100 ng of
purified recombinant MDA5 (OriGene, Rockville, MD),
diluted in phosphate buffered saline (PBS), and left to stand
overnight at 4∘C. Wells were incubated for 1 hour at room
temperature (RT) with blocking buffer (10% nonfat dry
milk in PBS). Plates were then washed (HRP Wash, INOVA
Diagnostic Inc., San Diego, CA); human serum samples
diluted 1 : 100 in blocking buffer were added in triplicate: two
toMDA5-coated wells and one to a PBS-coated well (without
antigen) to determine the background absorbance. Plates
were incubated at RT for 1 hour. After washing, HRP-labeled
goat anti-human IgG antibody (INOVA Diagnostic Inc.,
San Diego, CA) was added to each well, and plates were
incubated for 1 h at RT and washed again. Color development
was performed with peroxidase reagent TMB Chromogen
(INOVA Diagnostic Inc., San Diego, CA) and absorbances at
450 nm were determined. For each sample, the background
absorbance from the PBS-coated well was subtracted from
that of the correspondingMDA5-coated wells (the average of
the two results). Sample absorbance was expressed as optical
density units. The same positive serum (from patient 11,
confirmed by IP by Casciola Rosen, from Baltimore, USA)
was used as the reference in each assay.
2.4. Anti-MDA5 Immunoblot. Briefly, 5 𝜇g of purified recom-
binant MDA5 (OriGene, Rockville, MD) was run on 4%
to 12% polyacrylamide-SDS minigels with MOPS running
buffer, and western blot was performed on a nitrocellulose
membrane using the Invitrogen NuPAGE (Carlsbad, CA)
electrophoresis system. [20] MDA5-transferred nitrocellu-
lose was vertically cut into several strips and incubated for 1
hour at RT in PBS with 0.05% Tween (PBS-T) containing 3%
nonfat dry milk (blocking buffer). Each strip was then incu-
bated with the corresponding human serum sample diluted
1 : 100 in blocking buffer for 1 hour at RT. After washing,
phosphatase alkaline-labeled goat anti-human IgG antibody
(Dako, Glostrup, Denmark 1 : 2000) was added to each strip
and stripswere incubated for 1 hour at RT. Color development
was performed by phosphatase reagent (BCIP/NBT, Sigma-
Aldrich, St. Louis, MO). Based on signal intensity, the results
were classified into negative, weak positive (+), or positive
(++, +++) (Figure 1).
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Figure 1: Immunoblots showing the reactivity of IgG antibodies from dermatomyositis patients against commercially available purified
recombinant MDA5. Lanes 3 and 4 (+), 5 and 6 (++), and 7 and 8 (+++) were considered positive results. Lanes 1 and 2 corresponded to
negative serum samples. Dashed arrows are probably degradation products of MDA5.
2.5. Statistical Analysis. Associations between anti-MDA5
antibodies and qualitative variables were evaluated with
the chi-square and Fisher exact test. The strength of the
associations between variables was measured using odds
ratios (ORs) with 95% confidence intervals (CIs). TheMann-
Whitney 𝑈 test was used for comparisons of median values.
The corresponding area under the curve (AUC) of the ROC
analysis of anti-MDA5 antibody for detection of RP-ILD,
CADM, and total DM was analyzed with 95% of CIs. All
tests were two-sided, and probability (𝑃) values of <0.05 were
considered statistically significant. Cumulative survival rates
were estimated by the Kaplan-Meier test. The log-rank test
was also used to compare survival rates. All analyses were
performed with SPSS, version 19.0 (SPSS, Chicago, IL).
3. Results
One-hundred and seventeen adult DM patients, 15 of whom
had CADM, were included in the study. Anti-MDA5 was
determined by our in-house ELISA and immunoblot tech-
niques using a commercially available recombinant MDA5.
The cut-off value for a positive result on ELISA was estab-
lished at 0.188 absorbance units, which corresponded to 2
standard deviations above the mean value obtained for the
25 healthy controls. The other control subjects included 45
patients with polymyositis (PM), 30 with systemic sclerosis
(SSc), and 25 with systemic lupus erythematosus (SLE)
(Figure 2). Only two patients diagnosed with DM, 2 with PM,
and 1 with SSc showed weak anti-MDA5 reactivity by ELISA,
which was not confirmed by immunoblot; these results were
considered false positives. Anti-MDA5 antibodies detected
by ELISA and confirmed by immunoblot were only found
in DM patients. ROC curve analysis for the positivity of
anti-MDA5 of all patients with DM against controls and
CADM patients versus remaining DM disclosed an AUC
of 0.56, 95% CI 0.49–0.63 and 0.74, 95% CI 0.58–0.9,
respectively. Patients with the highest absorbance unit values
on ELISA also showed the strongest anti-MDA5 positivity on
immunoblotting.
Fourteen patients, 8 with CADM, tested positive for anti-
MDA5, which represents a prevalence of 12% of the DM
patients from our cohort. Median (range) age at diagnosis
of anti-MDA5 positive patients was 47 (28–60) years, which
did not differ significantly from the remainder of the cohort.
ANA was positive in 5 patients. Seven patients also tested
positive to anti-Ro52, but none of them was positive for any
antisynthetase antibody. Relevant clinical and immunological
findings are summarized in Table 1.
3.1. Relationship between Anti-MDA5 and RP-ILD. Intersti-
tial lung disease was present in 9 of the 14 (64.3%) patients
with anti-MDA5 autoantibodies, and the condition was
rapidly progressive in 8 patients. RP-ILD was more frequent
in patients with CADM, both in the anti-MDA5 positive
group (7 of 8 CADM versus 1 of 6 DM; 𝑃 < 0.05) and in
the overall cohort (8 of 15 CADMpatients versus 3 of 102 DM
patients; 𝑃 < 0.05). When RP-ILD was evaluated in relation
to anti-MDA5 positivity, a highly significant association was
observed between the two parameters. Thus, 8 of the 14
anti-MDA5-positive patients presented RP-ILD versus 3 of
the 103 anti-MDA5-negative patients (𝑃 < 0.05; OR: 44.4,
95% CI 9.3–212; AUC 0.84, 95% CI 0.68–1). Nevertheless, no
association was found between anti-MDA5 ELISA titers at
diagnosis of DM and development of a RP-ILD. Moreover,
6 of the 8 (75%) patients with anti-MDA5 and RP-ILD were
Ro52-positive in comparison to only 1 of the 6 (16%) patients
without RP-ILD.
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Figure 2: Representation of the anti-MDA5 ELISA test results in patients with dermatomyositis (DM) (𝑛 = 117) and controls groups:
polymyositis (PM) (𝑛 = 45), systemic sclerosis (SSc) (𝑛 = 30), systemic lupus erythematosus (SLE) (𝑛 = 25), and healthy controls (𝑛 = 25).
Panel (b) shows anti-MDA5 ELISA of patients with DM (𝑛 = 117) and individual subgroups of DM patients: rapidly progressive-interstitial
lung disease (RP-ILD) (𝑛 = 11) and clinically amyopathic dermatomyositis (CADM) (𝑛 = 15). The cut-off value for a positive result was
established at 0.188 absorbance units which corresponded to 2 standard deviations above the mean value obtained for the 25 healthy controls
(dashed line).
3.2. Relationship between Anti-MDA5 and Cutaneous Mani-
festations andCancer. TheCADMdiagnosis was significantly
associated with anti-MDA5 positive status (8 of 14 MDA5-
positive patients versus 7 of 103 MDA5-negative (𝑃 < 0.05;
OR: 18.3, 95% CI 4.9–67.6)). No differences were observed
in the frequency of Gottron’s papules, heliotrope rash,
photosensitivity, shawl or “V” sign, cuticular overgrowth,
calcinosis, or the presence of mechanic’s hands when the
anti-MDA5-positive and anti-MDA5-negative groups were
compared. Panniculitis was the only manifestation signif-
icantly associated with the presence of anti-MDA5 (5 out
of 14 anti-MDA5-positive versus 13 out of 103 anti-MDA5-
negative; 𝑃 < 0.05; OR: 3.85, 95% CI 1.11–13.27); nevertheless,
a multivariate analysis was not possible to be performed due
to methodological reasons.
Cancer was diagnosed in 4 out of 14 (28.6%) patients
with anti-MDA5 autoantibodies, and 3 (21%) of them fulfilled
criteria of CAM. However, no association was found between
anti-MDA5 autoantibodies and CAM (𝑃 > 0.05). A similar
result was obtained when we repeated the analysis after
excluding from the cohort the anti-TIF1𝛾-positive patients
(28 patients) in order to avoid a possible confounding
effect of the presence of these patients in the control
group.
3.3. Survival Rates of Anti-MDA5-Positive Patients. The cu-
mulative 70-month survival rate was significantly lower
(38%) in the group of patients with anti-MDA5 than in the
remainder of the cohort (62%) (log-rank test, 𝑃 < 0.05)
(Figure 3(a)). Comparison of cumulative 70-month survival
between anti-MDA5-associated ILD and antisynthetase-
associated ILD also showed a statistical difference (log-
rank test, 𝑃 < 0.05) (Figure 3(b)). No differences in 70-
month survival were observed between the CADM group
and the classic DM group in anti-MDA5- positive patients.
All groups were comparable in age, gender, and number
of immunosuppressive agents added to the corticosteroid
treatment. Differences in survival could not be attributed
to a higher proportion of “deaths directly related to cancer”
between groups.
4. Discussion
The results of this study prove the feasibility of detecting
antibodies against MDA5 in adult patients with DM by
in-house ELISA and immunoblot techniques using com-
mercially available recombinant MDA5 as the antigen. In
addition, the findings in our patients contribute to support
the previously reported association of anti-MDA5 antibody
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Figure 3: Cumulative 70-month survival rates for DM patients with and without anti-MDA5 antibody (a) and for DM patients with ILD
associated with anti-ARS or anti-MDA5 (b). The 70-month cumulative survival rates were calculated using the Kaplan-Meier test. The log-
rank test was also used to compare survival rates. ARS: aminoacyl-tRNA synthetase; DM: dermatomyositis; ILD: interstitial lung disease.
with RP-ILD and CADM. This association has been mainly
described in Asian patients. [1–6], and the only studies
performed in a white population have come from the United
States [7–9]. Our results in a large series of Mediterranean
patients from a single reference center, together with those
from other articles published on this topic, [1–8] indicate that
anti-MDA5 antibodies may be a hallmark of adult CADM
patients with RP-ILD regardless of their origin.
Furthermore, some authors have suggested an associa-
tion between this autoantibody and a specific, severe skin
vasculopathy in adult DM, characterized by vascular fibrin
deposition with variable perivascular inflammation [3, 7, 8].
We found an association only with panniculitis, one of the
mucocutaneous findings previously described by Fiorentino
et al. [8] in white adults with DM and anti-MDA5 antibody.
Although we routinely test all serum samples from
patients with inflammatory myopathies by immunoprecipi-
tation assays using 35S-protein-labeled HeLa cells, until the
development of our proposed method, we had not been
able to clearly identify patients with anti-140 kDa antibodies
(anti-CADM-140; i.e, anti-MDA5). In our analyses, this
polypeptide migrated to an area in which almost 70% of sera,
including those from normal subjects, immunoprecipitated
a weak line around 140 kDa. Hence, until anti-MDA5 was
described by Sato et al. [1, 6], andwe tested these patients with
a commercially available recombinantMDA5by our in-house
ELISA and immunoblot techniques, we were unable to rec-
ognize this autoantibody. Our positive patients correspond
to a period of 30 years of follow-up. Our first patient with
CADMandRP-ILD died nearly 20 years ago, and anti-MDA5
was detected in a stored frozen serum sample by our in-house
techniques.Thus, thesemethods could represent a significant
advancement in identification of this autoantibody, even in
laboratories with standard equipment.
Anti-Ro52 antibodies were present inmost of our patients
with RP-ILD and anti-MDA5, an association that has only
recently been reported in anti-MDA5-positive ILD patients
[9]. This fact confers relevant significance on anti-Ro52 as a
costimulatory autoantibody, a concept reported in patients
with antisynthetase syndrome [21, 22].
One patient was positive to both anti-MDA5 and anti-
TIF1𝛾. To our knowledge, this is the first description of this
association. Coexistence of two different myositis-specific
antibodies has been rarely reported [19, 23]. Hence, the
situation of this patient is intriguing and warrants further
investigation.
The clinical course of anti-MDA5-positive DM patients
can be divided into three groups. First (and most important
from the prognostic perspective), is the group of patients
with CADM and RP-ILD, who usually have a poor prog-
nosis and a mortality rate of nearly 50% despite aggressive
immunosuppressive therapy and even lung transplantation.
Second, the group with CADM and little lung involvement,
who show skin manifestations, such as ulcerations, palmar
pustules, and perhaps panniculitis, as was reported here. The
prognosis does not seem to be unfavorable in this group. And
finally, the third group of patients, who have ILD that is not
rapidly progressive and shows a disease pattern similar to
that of classic antisynthetase syndrome. [9] Differences in the
prognosis between the first and the third group may be due
to genetic background, and either early immunosuppressive
therapy or use of certain drugs, such as calcineurin inhibitors
[24].
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The existence of a clinical syndrome of rapidly progres-
sive ILD (usually in antisynthetase-negative patients) was
recognized some years ago [25], but the absence of useful
biomarkers made it difficult to characterize these patients.
The discovery of anti-MDA5 antibodies will help to better
define this population, facilitate an early diagnosis, establish
the prognosis, and ultimately enable the development of
randomized clinical trials to determine the optimal therapy
in anti-MDA5-positive patients with a poor prognosis.More-
over, as it has been recently described, anti-MDA5 antibody
measurement seems to be useful for monitoring disease
activity [13, 26].
As our results show, ELISA confirmed by immunoblot
with commercially available recombinant MDA5 antigen are
useful techniques for anti-MDA5 detection that can be reli-
ably performed in a standard laboratory setting, with poten-
tial application in clinical practice.
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